Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.

MLA

Konstantinopoulos, Panagiotis A., et al. “Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.” JAMA Oncology, vol. 8, no. 9, Sept. 2022, pp. 1317–22. EBSCOhost, https://doi.org/10.1001/jamaoncol.2022.2181.

APA

Konstantinopoulos, P. A., Gockley, A. A., Xiong, N., Krasner, C., Horowitz, N., Campos, S., Wright, A. A., Liu, J. F., Shea, M., Yeku, O., Castro, C., Polak, M., Lee, E. K., Sawyer, H., Bowes, B., Moroney, J., Cheng, S.-C., Tayob, N., Bouberhan, S., … Matulonis, U. A. (2022). Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncology, 8(9), 1317–1322. https://doi.org/10.1001/jamaoncol.2022.2181

Chicago

Konstantinopoulos, Panagiotis A, Allison A Gockley, Niya Xiong, Carolyn Krasner, Neil Horowitz, Susana Campos, Alexi A Wright, et al. 2022. “Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.” JAMA Oncology 8 (9): 1317–22. doi:10.1001/jamaoncol.2022.2181.